FMR LLC purchased a new position in shares of CeriBell (NASDAQ:CBLL - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 4,950,549 shares of the company's stock, valued at approximately $128,120,000. FMR LLC owned 13.82% of CeriBell at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Rhumbline Advisers purchased a new stake in shares of CeriBell during the fourth quarter worth approximately $320,000. Corebridge Financial Inc. acquired a new stake in shares of CeriBell during the 4th quarter worth about $158,000. PNC Financial Services Group Inc. acquired a new position in CeriBell in the 4th quarter valued at $47,000. Massachusetts Financial Services Co. MA purchased a new position in shares of CeriBell during the 4th quarter worth $10,750,000. Finally, Franklin Resources Inc. acquired a new stake in shares of CeriBell during the fourth quarter worth $12,460,000.
CeriBell Trading Up 2.5 %
Shares of NASDAQ CBLL traded up $0.36 during midday trading on Friday, hitting $14.85. 621,578 shares of the company's stock were exchanged, compared to its average volume of 268,776. The business's 50 day moving average is $20.31. CeriBell has a twelve month low of $10.01 and a twelve month high of $32.75.
CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The firm had revenue of $18.53 million during the quarter, compared to the consensus estimate of $17.55 million. Sell-side analysts forecast that CeriBell will post -2.46 earnings per share for the current fiscal year.
Analyst Ratings Changes
CBLL has been the topic of several research analyst reports. Canaccord Genuity Group reissued a "buy" rating and issued a $33.00 target price on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, CeriBell has an average rating of "Buy" and an average price target of $32.50.
Check Out Our Latest Research Report on CBLL
About CeriBell
(
Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Stories
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
